<?xml version="1.0" encoding="UTF-8"?>
<p>Despite the massive use of codeine, paracetamol, and ibuprofen for the relief of respiratory diseases, the clinical body of evidence supporting their use in flu is very low. These drugs are mostly used based on medical experience and clinicians are familiar with their benefits/risks profiles. These drugs have very common toxicities and their adverse effects are potentially dangerous in the context of COVID-19 (
 <xref rid="B257" ref-type="bibr">Jóźwiak-Bebenista and Nowak, 2014</xref>; 
 <xref rid="B122" ref-type="bibr">Drugs.com, 2020a</xref>; 
 <xref rid="B123" ref-type="bibr">Drugs.com, 2020b</xref>).
</p>
